RU2016148887A3 - - Google Patents

Download PDF

Info

Publication number
RU2016148887A3
RU2016148887A3 RU2016148887A RU2016148887A RU2016148887A3 RU 2016148887 A3 RU2016148887 A3 RU 2016148887A3 RU 2016148887 A RU2016148887 A RU 2016148887A RU 2016148887 A RU2016148887 A RU 2016148887A RU 2016148887 A3 RU2016148887 A3 RU 2016148887A3
Authority
RU
Russia
Application number
RU2016148887A
Other versions
RU2707730C2 (ru
RU2016148887A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53284528&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016148887(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of RU2016148887A publication Critical patent/RU2016148887A/ru
Publication of RU2016148887A3 publication Critical patent/RU2016148887A3/ru
Application granted granted Critical
Publication of RU2707730C2 publication Critical patent/RU2707730C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
RU2016148887A 2014-05-15 2015-05-13 Пиридиновые соединения пладиенолида и способы применения RU2707730C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461993423P 2014-05-15 2014-05-15
US61/993,423 2014-05-15
PCT/US2015/030464 WO2015175594A1 (en) 2014-05-15 2015-05-13 Pladienolide pyridine compounds and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2019124012A Division RU2807278C2 (ru) 2014-05-15 2015-05-13 Пиридиновые соединения пладиенолида и способы применения

Publications (3)

Publication Number Publication Date
RU2016148887A RU2016148887A (ru) 2018-06-18
RU2016148887A3 true RU2016148887A3 (ru) 2018-12-11
RU2707730C2 RU2707730C2 (ru) 2019-11-29

Family

ID=53284528

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016148887A RU2707730C2 (ru) 2014-05-15 2015-05-13 Пиридиновые соединения пладиенолида и способы применения

Country Status (35)

Country Link
US (1) US9481669B2 (ru)
EP (2) EP3143016B1 (ru)
JP (1) JP6067943B1 (ru)
KR (2) KR102146726B1 (ru)
CN (1) CN107074827B (ru)
AR (1) AR100431A1 (ru)
AU (1) AU2015259237B2 (ru)
BR (1) BR112016026638B1 (ru)
CA (1) CA2947754C (ru)
CL (1) CL2016002835A1 (ru)
CY (1) CY1121550T1 (ru)
DK (1) DK3143016T3 (ru)
ES (1) ES2712401T3 (ru)
HR (1) HRP20190432T1 (ru)
HU (1) HUE041838T2 (ru)
IL (1) IL248529B (ru)
JO (1) JO3668B1 (ru)
LT (1) LT3143016T (ru)
MA (1) MA39915B1 (ru)
ME (1) ME03417B (ru)
MX (2) MX2016014997A (ru)
MY (1) MY195081A (ru)
PE (1) PE20170384A1 (ru)
PH (1) PH12016502249A1 (ru)
PL (1) PL3143016T3 (ru)
PT (1) PT3143016T (ru)
RS (1) RS58400B1 (ru)
RU (1) RU2707730C2 (ru)
SG (1) SG11201609693XA (ru)
SI (1) SI3143016T1 (ru)
TR (1) TR201902328T4 (ru)
TW (1) TWI634115B (ru)
UA (1) UA119458C2 (ru)
WO (1) WO2015175594A1 (ru)
ZA (1) ZA201607354B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10889866B2 (en) 2015-09-01 2021-01-12 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic SF3B1 mutants
CN108473479B (zh) * 2015-11-18 2024-05-07 卫材研究发展管理有限公司 普拉二烯内酯吡啶化合物的固态形式和使用方法
CA3056389A1 (en) 2017-03-15 2018-09-20 Eisai R&D Management Co., Ltd. Spliceosome mutations and uses thereof
CN111727059A (zh) 2017-10-31 2020-09-29 卫材研究发展管理有限公司 包含至少一种剪接体调控剂和至少一种选自BCL2抑制剂、BCL2/BCLxL抑制剂和BCLxL抑制剂的抑制剂的组合及其使用方法
WO2019199667A2 (en) * 2018-04-09 2019-10-17 Keaney Gregg F Certain pladienolide compounds and methods of use
EP3774760A1 (en) * 2018-04-12 2021-02-17 Eisai R&D Management Co., Ltd. Pladienolide derivatives as spliceosome targeting agents for treating cancer
EP3801523A2 (en) * 2018-06-01 2021-04-14 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
IL262658A (en) * 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
EP4240360A1 (en) 2020-11-04 2023-09-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
EP4361136A1 (en) * 2021-06-18 2024-05-01 Universidad De Córdoba Compound for the treatment of glioblastoma
CN113876771B (zh) * 2021-11-12 2022-09-23 中国医学科学院基础医学研究所 一种靶向pabpc1的小分子药物及其在慢性髓系白血病中的应用
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312681B (en) * 2001-02-01 2009-08-01 Novel physiologically active substance
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
US7576204B2 (en) 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
MXPA05001104A (es) 2002-07-31 2005-09-08 Eisai Co Ltd Nuevas sustancias fisiologicamente activas.
WO2004037212A2 (en) 2002-10-24 2004-05-06 Sepracor, Inc. Compositions comprising zopiclone derivatives and methods of making and using the same
AU2003284469B2 (en) 2002-11-29 2008-02-21 Eisai R&D Management Co., Ltd. Process for producing macrolide compound
JP4441489B2 (ja) 2003-11-27 2010-03-31 メルシャン株式会社 マクロライド系化合物の水酸化に関与するdna
ES2345493T3 (es) 2003-11-28 2010-09-24 Kanagawa Academy Of Science And Technology Metodo de deteccion de cancer de higado, diagnostico de cancer de higado y remedio para el cancer.
US20070199741A1 (en) 2004-07-02 2007-08-30 Kenji Noumi Combined Weighing Apparatus
ATE538203T1 (de) 2004-07-20 2012-01-15 Eisai R&D Man Co Ltd Für an der biosynthese von pladienolid beteiligtes polypeptid codierende dna
TW200716744A (en) * 2005-05-26 2007-05-01 Eisai R&D Man Co Ltd Genetically modified microorganism and process for production of macrolide compound using the microorganism
EP1935893A4 (en) 2005-10-13 2009-07-22 Eisai R&D Man Co Ltd TOTAL SYNTHESIS OF PLADIENOLIDE B AND PLADIENOLIDE D
JPWO2008111464A1 (ja) * 2007-03-05 2010-06-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スプライシング異常を指標とする抗ガン剤の作用検定方法
US20080312317A1 (en) 2007-04-12 2008-12-18 Eisai R&D Management Co., Ltd. 12 membered-ring macrolactam derivatives

Also Published As

Publication number Publication date
ME03417B (me) 2020-01-20
MX2020004476A (es) 2021-12-08
NZ764190A (en) 2023-11-24
MA39915B1 (fr) 2019-05-31
EP3143016B1 (en) 2018-12-12
MX2016014997A (es) 2017-06-29
HRP20190432T1 (hr) 2019-04-19
JO3668B1 (ar) 2020-08-27
EP3143016A1 (en) 2017-03-22
US20150329528A1 (en) 2015-11-19
KR101710318B1 (ko) 2017-02-24
TW201625596A (zh) 2016-07-16
BR112016026638A2 (ru) 2017-08-15
PH12016502249A1 (en) 2017-02-06
HUE041838T2 (hu) 2019-05-28
UA119458C2 (uk) 2019-06-25
MY195081A (en) 2023-01-09
NZ725603A (en) 2023-11-24
EP3514154B1 (en) 2022-08-03
SG11201609693XA (en) 2016-12-29
JP2017505282A (ja) 2017-02-16
CL2016002835A1 (es) 2017-04-17
IL248529B (en) 2019-11-28
CN107074827A (zh) 2017-08-18
ZA201607354B (en) 2018-05-30
CA2947754A1 (en) 2015-11-19
AU2015259237A1 (en) 2016-11-10
CA2947754C (en) 2024-01-02
AR100431A1 (es) 2016-10-05
EP3514154A1 (en) 2019-07-24
AU2015259237B2 (en) 2019-08-15
TR201902328T4 (tr) 2019-03-21
DK3143016T3 (en) 2019-04-08
IL248529A0 (en) 2016-12-29
TWI634115B (zh) 2018-09-01
RS58400B1 (sr) 2019-04-30
MA39915A (fr) 2017-03-22
KR102146726B1 (ko) 2020-08-21
RU2707730C2 (ru) 2019-11-29
CY1121550T1 (el) 2020-05-29
ES2712401T3 (es) 2019-05-13
JP6067943B1 (ja) 2017-01-25
KR20160082256A (ko) 2016-07-08
WO2015175594A1 (en) 2015-11-19
PL3143016T3 (pl) 2019-04-30
PE20170384A1 (es) 2017-05-11
US9481669B2 (en) 2016-11-01
CN107074827B (zh) 2020-12-18
LT3143016T (lt) 2019-06-10
BR112016026638B1 (pt) 2022-08-02
RU2016148887A (ru) 2018-06-18
SI3143016T1 (sl) 2019-04-30
KR20170021899A (ko) 2017-02-28
RU2019124012A (ru) 2019-08-12
PT3143016T (pt) 2019-02-27

Similar Documents

Publication Publication Date Title
BR112016019490A2 (ru)
BR112015027867A2 (ru)
BR112016016689A2 (ru)
BR112016023418A2 (ru)
BR112016021673A2 (ru)
BR112016019583A2 (ru)
BR112016030530A2 (ru)
BR112016023360A2 (ru)
RU2016148887A3 (ru)
BR112016015645A2 (ru)
BR112016022590A2 (ru)
BR112016018694A2 (ru)
BR112016021674A2 (ru)
BR112016020946A2 (ru)
BR112016025754A2 (ru)
BR112016017717A2 (ru)
BR112016026603A2 (ru)
BR112016022820A2 (ru)
BR112016022557A2 (ru)
BR112016026226A2 (ru)
BR112016019965A2 (ru)
JP1536726S (ru)
BR112016022075A2 (ru)
JP1522725S (ru)
JP1517219S (ru)